Effect of Concurrent Chemoradiation Therapy on Respiratory Muscle Performance, Lung Function and Functional Capacity in Patients With Local Esophagus Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effect of concurrent chemoradiation therapy on respiratory muscle performance, lung function and functional capacity in patients with local esophagus cancer.

Detailed Description
-----------------
This is a prospective observational study design. A total of 45 patients with newly diagnosed esophageal cancer will be recruited from the Mackay Memorial Hospital. All tests will be performed at baseline (prior to cancer treatment), weekly during treatment, prior to surgery, and one month after surgery. Tests will include demographic data collection, respiratory muscle performance (maximal inspiratory and expiratory pressure tests combined with diaphragmatic surface electromyography, and pulmonary functional test), dyspnea, and the functional exercise test (6-min walk test).Repeated measure ANOVA will be used for analyzing difference of parameters among various time points.

Official Title
-----------------
Effect of Concurrent Chemoradiation Therapy on Respiratory Muscle Performance, Lung Function and Functional Capacity in Patients With Local Esophagus Cancer

Conditions
-----------------
Esophageal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: newly diagnosed primary esophageal cancer, aged more than 20 years, and communicate without difficulty Exclusion Criteria: inability to perform inspiratory muscle training, the presence of unstable angina or myocardial infarction in recently one month, cannot cooperate with training protocols, and pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of maximal inspiratory pressure (MIP) | Change from baseline MIP at the end of each week's treatment, and 2 weeks after the completion of treatment | Baseline, weekly during treatment, and 2 weeks after the completion of treatment | 
| Change of diaphragmatic surface electromyography (EMGdi) | Change from baseline EMGdi at the end of each week's treatment, and 2 weeks after the completion of treatment | Baseline, weekly during treatment, and 2 weeks after the completion of treatment | 
| Change of forced expiratory volume in one second (FEV1) | Change from baseline FEV1 at the end of each week's treatment, and 2 weeks after the completion of treatment | Baseline, weekly during treatment, and 2 weeks after the completion of treatment | 
| Change of forced vital capacity (FVC) | Change from baseline FVC at the end of each week's treatment, and 2 weeks after the completion of treatment | Baseline, weekly during treatment, and 2 weeks after the completion of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of functional exercise capacity | Change from baseline 6-minute walking distance at the end of each week's treatment, and 2 weeks after the completion of treatment | Baseline, weekly during treatment, and 2 weeks after the completion of treatment | 
| Change of dyspnea | Change from baseline Modified Borg Dyspnea score at the end of each week's treatment, and 2 weeks after the completion of treatment | Baseline, weekly during treatment, and 2 weeks after the completion of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Respiratory muscle strength, Diaphragmatic surface electromyography, Functional capacity